McGarrah Robert W, Kelly Jacob P, Craig Damian M, Haynes Carol, Jessee Ryan C, Huffman Kim M, Kraus William E, Shah Svati H
Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC;
Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Clin Chem. 2017 Jan;63(1):288-296. doi: 10.1373/clinchem.2016.261636. Epub 2016 Nov 3.
Evidence suggests that systemic inflammation may adversely impact HDL function. In this study we sought to evaluate the independent and incremental predictive performance of GlycA-a novel serum inflammatory biomarker that is an aggregate measure of enzymatically glycosylated acute phase proteins-and HDL subclasses on adverse events in a retrospective observational study of a secondary prevention population and to understand a priori defined potential interactions between GlycA and HDL subclasses.
GlycA and HDL subclasses were measured using proton nuclear magnetic resonance spectroscopy in 7617 individuals in the CATHGEN (CATHeterization GENetics) cardiac catheterization biorepository.
GlycA was associated with presence [odds ratio (OR) 1.07 (1.02-1.13), P = 0.01] and extent [OR 1.08 (1.03, 1.12) P < 0.0005] of coronary artery disease and with all-cause mortality [hazard ratio (HR) 1.34 (1.29-1.39), P < 0.0001], cardiovascular mortality [1.37 (1.30-1.45), P < 0.0001] and noncardiovascular mortality [1.46 (1.39-1.54) P < 0.0001] in models adjusted for 10 cardiovascular risk factors. GlycA and smaller HDL subclasses had independent but opposite effects on mortality risk prediction, with smaller HDL subclasses being protective [HR 0.69 (0.66-0.72), P < 0.0001]. There was an interaction between GlycA and smaller HDL subclasses-increasing GlycA concentrations attenuated the inverse association of smaller HDL subclasses with mortality. Adding GlycA and smaller HDL subclasses into the GRACE (Global Registry of Acute Coronary Events) and Framingham Heart Study Risk Scores improved mortality risk prediction, discrimination and reclassification.
These findings highlight the interaction of systemic inflammation and HDL with clinical outcomes and may increase precision for clinical risk assessment in secondary prevention populations.
有证据表明,全身炎症可能会对高密度脂蛋白(HDL)功能产生不利影响。在本研究中,我们试图在一项针对二级预防人群的回顾性观察研究中,评估糖化终产物(GlycA)——一种新型血清炎症生物标志物,它是酶糖基化急性期蛋白的综合指标——和HDL亚类对不良事件的独立及增量预测性能,并了解GlycA与HDL亚类之间预先定义的潜在相互作用。
在心脏导管插入术生物样本库CATHGEN(心脏导管插入术遗传学)中的7617名个体中,使用质子核磁共振波谱法测量GlycA和HDL亚类。
在针对10种心血管危险因素进行校正的模型中,GlycA与冠状动脉疾病的存在[比值比(OR)1.07(1.02 - 1.13),P = 0.01]和程度[OR 1.08(1.03,1.12),P < 0.0005]相关,并且与全因死亡率[风险比(HR)1.34(1.29 - 1.39),P < 0.0001]、心血管死亡率[1.37(1.30 - 1.45),P < 0.0001]和非心血管死亡率[1.46(1.39 - 1.54),P < 0.0001]相关。GlycA和较小的HDL亚类对死亡风险预测具有独立但相反的影响,较小的HDL亚类具有保护作用[HR 0.69(0.66 - 0.72),P < 0.0001]。GlycA与较小的HDL亚类之间存在相互作用——GlycA浓度升高会减弱较小的HDL亚类与死亡率之间的负相关。将GlycA和较小的HDL亚类纳入全球急性冠状动脉事件注册研究(GRACE)和弗雷明汉心脏研究风险评分中,可改善死亡风险预测、区分能力和重新分类。
这些发现突出了全身炎症和HDL与临床结局之间的相互作用,并可能提高二级预防人群临床风险评估的准确性。